Loading...
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James, R Glynne-Jones, R Meadows, H Cunningham, D Myint, A Saunders, Mark P Maughan, T McDonald, A Essapen, S Leslie, M
James, R
Glynne-Jones, R
Meadows, H
Cunningham, D
Myint, A
Saunders, Mark P
Maughan, T
McDonald, A
Essapen, S
Leslie, M
Citations
Altmetric:
Abstract
Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival.
Affiliation
Description
Date
2013-05
Publisher
Collections
Keywords
Type
Article
Citation
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. 2013, 14 (6):516-24 Lancet Oncol